Based on our findings that patients with CRC whose tumours exhibit high TGFBI immunoreactivity have a poor outcome and that the levels of TGFBI, determined by ELISA, are markedly increased in sEV-Ps, exomeres and supermeres isolated from the plasma of patients with CRC compared with those isolated from control individuals, we propose that TGFBI may be a useful marker in liquid biopsies for patients with CRC. This evidence concerns the gene TGFBI and neoplasm.